指南与共识造血干细胞移植与细胞治疗

接受嵌合抗原受体T细胞治疗患者的免疫相关不良事件管理:ASCO指南

Management of Immune-Related Adverse Events in Patients Treated With Chimeric Antigen Receptor T-Cell Therapy: ASCO Guideline.
指南 / 共识 · J Clin Oncol · 2021-11-01

该指南由多学科专家组制定,系统综述2017至2021年文献,共纳入35篇合格出版物,因高质量证据缺乏,推荐基于专家共识。推荐涵盖细胞因子释放综合征、免疫效应细胞相关神经毒性综合征、B细胞发育不全、血细胞减少和感染等常见毒性的识别、检查、评估与管理。

要点

  • 多数CAR T细胞短期毒性以支持治疗起始,反应不足者可能需药物干预。
  • 中重度免疫效应细胞相关神经毒性综合征应使用皮质类固醇和支持治疗。
  • prolonged或重度细胞因子释放综合征使用托珠单抗,可联用或不联用皮质类固醇。

核心结论

  • 因高质量证据缺乏,指南推荐基于专家共识,涵盖CAR T细胞相关常见毒性的识别、检查、评估与管理。

研究设计与样本

  • 多学科专家组(肿瘤内科、神经科、血液科、急诊医学、护理、试验专家和倡导专家)制定指南,采用系统文献综述与非正式共识流程。
  • 系统综述聚焦2017至2021年发表的证据,共识别35篇合格出版物。

主要发现

  • 系统综述识别35篇合格出版物。
  • 因高质量证据缺乏,推荐基于专家共识。

关键数值与推荐

  • 多数患者短期CAR T细胞相关毒性管理以支持治疗起始,反应不足者可能需药物干预。
  • prolonged或重度CAR T细胞相关细胞因子释放综合征治疗包括托珠单抗,可联用或不联用皮质类固醇。
  • 中重度免疫效应细胞相关神经毒性综合征应使用皮质类固醇和支持治疗。

临床怎么用

  • 指南推荐用于CAR T细胞治疗患者常见毒性(细胞因子释放综合征、免疫效应细胞相关神经毒性综合征、B细胞发育不全、血细胞减少和感染)的识别、检查、评估与管理。

局限性

  • 因高质量证据缺乏,推荐基于专家共识。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To increase awareness, outline strategies, and offer guidance on the recommended management of immune-related adverse events (irAEs) in patients treated with chimeric antigen receptor (CAR) T-cell therapy. METHODS: A multidisciplinary panel of medical oncology, neurology, hematology, emergency medicine, nursing, trialists, and advocacy experts was convened to develop the guideline. Guideline development involved a systematic literature review and an informal consensus process. The systematic review focused on evidence published from 2017 to 2021. RESULTS: The systematic review identified 35 eligible publications. Because of the paucity of high-quality evidence, recommendations are based on expert consensus. RECOMMENDATIONS: The multidisciplinary team issued recommendations to aid in the recognition, workup, evaluation, and management of the most common CAR T-cell-related toxicities, including cytokine release syndrome, immune effector cell-associated neurotoxicity syndrome, B-cell aplasia, cytopenias, and infections. Management of short-term toxicities associated with CAR T cells begins with supportive care for most patients, but may require pharmacologic interventions for those without adequate response. Management of patients with prolonged or severe CAR T-cell-associated cytokine release syndrome includes treatment with tocilizumab with or without a corticosteroid. On the basis of the potential for rapid decline, patients with moderate to severe immune effector cell-associated neurotoxicity syndrome should be managed with corticosteroids and supportive care.Additional information is available at www.asco.org/supportive-care-guidelines.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Santomasso BD, Nastoupil LJ, Adkins S, et al. Management of Immune-Related Adverse Events in Patients Treated With Chimeric Antigen Receptor T-Cell Therapy: ASCO Guideline. J Clin Oncol. 2021. PMID: 34724386. doi:10.1200/JCO.21.01992

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。